Beyond this, studies have demonstrated significant heterogeneity in treatment responses among colorectal cancer (CRC) subtypes, with PD-1 inhibitors exhibiting limited efficacy in microsatellite instability-low (MSI-L) CRC compared to improved outcomes in microsatellite instability-high (MSI-H) patients (6). This evidence concerns the gene PDCD1 and colorectal cancer.